Form 4: KalVista Director Unkart Sells Options in Chiesi Merger

KalVista Pharmaceuticals Director Edward W. Unkart disposed of all his stock options as part of the company's acquisition by Chiesi Farmaceutici S.p.A. for $27.00 per share.

Summary

• Edward W. Unkart, a Director of KalVista Pharmaceuticals, Inc. (KALV), reported the disposition of his stock options.
• The disposition occurred on June 11, 2026, as a result of the merger of KalVista Pharmaceuticals, Inc. with Skyline Merger Sub, Inc., a wholly-owned subsidiary of Chiesi Farmaceutici S.p.A.
• Under the Merger Agreement dated April 29, 2026, Chiesi Farmaceutici S.p.A. acquired KalVista for $27.00 per share in a cash tender offer.
• Options with an exercise price less than $27.00 were fully vested, cancelled, and converted into a cash payment equal to the difference between the merger consideration and the exercise price, multiplied by the number of shares.
• Options with an exercise price equal to or greater than $27.00 were cancelled for no consideration.
• Unkart disposed of a total of 109,000 stock options, all of which had exercise prices below the $27.00 merger consideration.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a positive event for KalVista shareholders and option holders, as the company was acquired at a fixed cash price, providing liquidity and value realization, particularly for in-the-money options.

Positives

• The merger consideration of $27.00 per share provided a clear exit strategy and value realization for shareholders and option holders with in-the-money options.
• Edward W. Unkart's in-the-money stock options were fully vested and converted into cash payments, indicating a positive financial outcome for the director.

Negatives

• Options with an exercise price equal to or greater than the $27.00 merger consideration were cancelled for no consideration, resulting in a loss of potential value for holders of such options (though none were reported by Unkart in this filing).
• KalVista Pharmaceuticals, Inc. ceased to be an independent publicly traded entity, becoming a wholly-owned subsidiary of Chiesi Farmaceutici S.p.A.

Industry Context

StockSavvy.ai notes that the acquisition of KalVista Pharmaceuticals by Chiesi Farmaceutici S.p.A. reflects a broader trend in the pharmaceutical and biotechnology sectors where larger companies acquire smaller, innovative firms to expand their pipeline or market presence, particularly in specialized therapeutic areas. This transaction indicates a successful exit for KalVista's investors and a strategic move for Chiesi to potentially integrate KalVista's assets.

Comparison to Industry Standards

• The $27.00 per share merger consideration for KalVista Pharmaceuticals, Inc. can be benchmarked against recent acquisitions in the rare disease or specialty pharmaceutical space. For instance, Sanofi's acquisition of Kadmon Holdings for $1.9 billion (approx. $9.50/share) or Alexion's acquisition of Portola Pharmaceuticals for $1.4 billion (approx. $18/share) involved similar strategic plays for pipeline assets.
• The premium paid for KalVista would need to be assessed against its pre-announcement trading price and analyst price targets to determine its competitiveness relative to industry averages for M&A transactions in the biotech sector, which often see premiums ranging from 30% to 70%.

Corporate Governance

Stakeholder Impact

• Shareholders: Received $27.00 per share in cash, providing a definitive return on investment.
• Option Holders: In-the-money options were converted to cash, while out-of-the-money options were cancelled without consideration.
• Employees: KalVista employees are now part of Chiesi Farmaceutici S.p.A., potentially impacting employment terms, benefits, and corporate culture.
• Management: Existing management roles and responsibilities likely changed as KalVista became a subsidiary.

Next Steps

• KalVista Pharmaceuticals, Inc. will operate as a wholly-owned subsidiary of Chiesi Farmaceutici S.p.A.
• Integration of KalVista's operations and pipeline into Chiesi's structure.

Key Dates

Recommendation

The company, KalVista Pharmaceuticals, Inc., has been acquired by Chiesi Farmaceutici S.p.A. and is no longer publicly traded. Shareholders would have received $27.00 per share in cash. Therefore, for existing shareholders, the transaction is complete, effectively a 'hold' until the cash is received. For prospective investors, there is no stock available for purchase or sale.

Keywords

KalVista Pharmaceuticals, KALV, Chiesi Farmaceutici, Merger, Acquisition, Stock Options, Form 4, Insider Transaction, Beneficial Ownership, Director, Cash Tender Offer